OKYO Pharma Limited
OKYO · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.05 | -0.00 | 0.00 |
| FCF Yield | -3.13% | -0.71% | -5.56% | -0.01% |
| EV / EBITDA | -6.86 | -19,927.54 | 111.01 | -5,447.57 |
| Quality | ||||
| ROIC | 39.42% | 27.24% | 0.12% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 90.16 | 0.34 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -550.87% | -8,856.23% | 60.31% | -61.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.22 | 590.41 | 117.92 | 0.00 |
| Interest Coverage | -33.37 | -3.97 | -6.67 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -551,589.40 | -678,676.86 | -163,659.31 | 0.00 |